Palvella Therapeutics (PVLA) Q3 2026 earnings summary

Executive summary

• FDA accepted the QTORIN rapamycin NDA for microcystic lymphatic malformations and granted Priority Review; PDUFA target date is February 28, 2027.

• If approved, a standalone U.S. launch is planned for H1 2027, with commercial, medical affairs, and patient-services capabilities under development.

• QTORIN programs span microcystic LMs, cutaneous venous malformations, clinically significant angiokeratomas, and DSAP.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $236.7M at September 30, 2026.

• Q3 R&D expense was $10.8M vs. $6.5M YoY; G&A was $11.9M vs. $3.6M, reflecting development, manufacturing, headcount, and professional services.

• Q3 operating expenses were $22.7M vs. $10.2M YoY; net loss was $24.6M vs. $11.3M.

• 9M operating expenses were $59.0M vs. $27.3M; net loss was $62.3M vs. $29.0M.

Outlook and guidance

• A standalone U.S. launch is planned for H1 2027 if approved; the PDUFA target date is February 28, 2027.

• Phase 3 cutaneous venous malformation trial initiation and Phase 2 DSAP trial initiation are anticipated in Q4 2026.

• LOTU Phase 2 topline results for clinically significant angiokeratomas are expected in H2 2027; Phase 2 data for another QTORIN rapamycin indication are also expected in H2 2027.

• Existing cash is expected to fund at least 12 months of planned operations; the current plan anticipates funding launch preparation and pipeline programs, with no near-term revenue or operating cash flow expected.

• Launch planning includes a field team of more than 70 members, including approximately 40 frontline sales representatives.